TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,090 JPY | -1.09% |
|
+0.02% | +0.89% |
| Sales 2024 * | 4,099B 26.33B | Sales 2025 * | 4,028B 25.88B | Capitalization | 6,488B 41.68B |
|---|---|---|---|---|---|
| Net income 2024 * | 134B 861M | Net income 2025 * | 234B 1.5B | EV / Sales 2024 * | 2.5 x |
| Net Debt 2024 * | 3,771B 24.22B | Net Debt 2025 * | 3,438B 22.08B | EV / Sales 2025 * | 2.46 x |
| P/E ratio 2024 * |
46.9
x | P/E ratio 2025 * |
27.9
x | Employees | 49,095 |
| Yield 2024 * |
4.55% | Yield 2025 * |
4.59% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | -1.09% | ||
| 1 week | +0.02% | ||
| Current month | -2.25% | ||
| 1 month | -6.30% | ||
| 3 months | -5.76% | ||
| 6 months | -6.02% | ||
| Current year | +0.89% |
1 week
4 038.00
4 151.00
1 month
4 038.004 414.00
Current year
4 038.004 494.00
1 year
3 900.004 873.00
3 years
2 993.004 873.00
5 years
2 894.504 873.00
10 years
2 894.506 693.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 24.44% | 15 M€ | +5.53% | ||
| 5.00% | 284 M€ | +22.43% | ||
| 3.80% | 1,552 M€ | +16.65% | ||
| 3.43% | 251 M€ | +13.17% | ||
| 3.26% | 57 M€ | +17.93% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4,090 | -1.09% | 2 910 500 |
| 24-04-24 | 4,135 | +0.32% | 3,228,000 |
| 24-04-23 | 4,122 | -0.15% | 2,747,100 |
| 24-04-22 | 4,128 | +1.45% | 3,521,200 |
| 24-04-19 | 4,069 | -0.49% | 5,442,500 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,135
JPY
Average target price
4,779
JPY
Spread / Average Target
+15.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.89% | 41.84B | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 4502 Stock
